A Bcl-2 inhibitor that has FDA approval for treatment of several leukemias reversed lung fibrosis in a bleomycin mouse model. BIRMINGHAM, Ala. – Researchers have reversed lung fibrosis in a mouse ...
The majority of the persisting sequelae in coronavirus disease 2019 (COVID-19) survivors with pulmonary disposition include fatigue, chest pain, and chronic lung disease, all of which directly affect ...
Researchers have reversed lung fibrosis in a mouse model of idiopathic pulmonary fibrosis. Mice were given bleomycin for 12 days to establish lung fibrosis, and then treated daily until 21 days with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results